Physician profile
Amir Harari
NPI 1578537353
$361,322.43
in general payments reported to CMS, 2019-2025
64 companies · $51K in 2025
The $51K reported for 2025 was more than what 96% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72K · 2020: $22K · 2021: $54K · 2022: $68K · 2023: $42K · 2024: $51K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $114K · Food and Beverage: $12K · Consulting Fee: $10K · Travel and Lodging: $6,941 · Honoraria: $500 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $300 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,202.69 |
| Food and Beverage | $12,306.56 |
| Consulting Fee | $10,012.72 |
| Travel and Lodging | $6,940.74 |
| Honoraria | $500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $300.00 |
| Education | $127.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $255,721.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $29,491.42 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $26,293.80 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Ascensia Diabetes Care US INC. | $19,538.39 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $9,826.65 | 2019 | |
| Senseonics, Incorporated | $8,144.00 | 2019-2025 | Eversense |
| Corcept Therapeutics | $2,577.58 | 2019-2025 | Korlym |
| Amgen INC. | $805.51 | 2019-2025 | Tepezza, Evenity, Prolia |
| Radius Health, INC. | $631.22 | 2019-2025 | Tymlos |
| Dexcom, INC. | $560.94 | 2019-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $535.40 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Intra-Sana Laboratories | $500.00 | 2023 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Abbvie INC. | $491.32 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $462.40 | 2019-2025 | Jardiance |
| Medtronic, INC. | $459.83 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Inceptiv |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $449.01 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Astrazeneca Pharmaceuticals Lp | $408.47 | 2019-2024 | Farxiga |
| Recordati_rare_diseases_inc. | $406.13 | 2023-2025 | Isturisa, Signifor Lar |
| Sanofi-Aventis U.S. LLC | $382.85 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $271.57 | 2019-2025 | Unithroid |
| Antares Pharma, INC. | $216.76 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $215.67 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $211.56 | 2019-2025 | Strensiq |
| Medtronic Minimed, INC. | $205.39 | 2019 | |
| Sequel Med Tech, LLC | $186.98 | 2025 | Twiist |
| Insulet Corporation | $181.19 | 2020-2025 | Omnipod |
| Astellas Pharma US INC | $169.08 | 2023-2025 | Veozah |
| Madrigal Pharmaceuticals | $167.91 | 2024-2025 | Rezdiffra, Resmetirom |
| Lifescan, INC. | $156.75 | 2019-2020 | |
| Cequr Corporation | $152.16 | 2023-2024 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $135.59 | 2019 | |
| Tandem Diabetes Care, INC. | $114.68 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $113.81 | 2024-2025 | Yorvipath |
| Mannkind Corporation | $89.34 | 2019-2024 | |
| Verity Pharmaceuticals INC. | $76.57 | 2024-2025 | Tlando |
| Novartis Pharmaceuticals Corporation | $67.60 | 2024-2025 | |
| Halozyme INC | $56.58 | 2023 | |
| Neurocrine Biosciences, INC. | $55.75 | 2024-2025 | |
| Amarin Pharma, INC. | $53.38 | 2019-2020 | |
| Tolmar, INC. | $52.73 | 2024-2025 | Jatenzo |
| Amphastar Pharmaceuticals, INC. | $50.80 | 2025 | |
| Amryt Pharma Holdings Ltd | $48.02 | 2023 | Mycapssa |
| Ge Healthcare | $47.31 | 2019 | |
| Averitas Pharma INC. | $43.20 | 2024 | Qutenza |
| Shire North American Group INC | $39.56 | 2019 | |
| Embecta Corp. | $36.25 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ibsa Pharma INC. | $33.73 | 2019 | |
| Alnylam Pharmaceuticals INC. | $33.11 | 2023 | Givlaari |
| Valeritas, INC. | $32.44 | 2019 | |
| Sandoz INC. | $30.98 | 2025 | |
| Janssen Scientific Affairs, LLC | $30.61 | 2019 | |
| Glaxosmithkline, LLC. | $27.11 | 2025 | Shingrix, Arexvy |
| Kyowa Kirin, INC. | $25.89 | 2024 | Crysvita |
| Globus Medical, INC. | $24.76 | 2025 | Omnia |
| Chiesi USA, INC. | $23.96 | 2025 | Myalept |
| Soleno Therapeutics, INC. | $21.44 | 2025 | Vykat Xr |
| Vivus LLC | $21.38 | 2019 | |
| Inspire Medical Systems, INC. | $19.66 | 2025 | Inspire |
| Horizon Therapeutics Plc | $19.43 | 2022 | |
| Ionis Pharmaceuticals, INC. | $17.03 | 2025 | Tryngolza |
| Companion Medical, INC. | $16.13 | 2019 | |
| Rhythm Pharmaceuticals, INC. | $14.79 | 2025 | Imcivree |
| Clarus Therapeutics INC. | $13.91 | 2021 | |
| Endo Pharmaceuticals INC. | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Harari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.